Navigation Links
Microdermics Closes $1 Million Funding Round to Scale Technology to Replace Hypodermic Needles
Date:4/20/2017

Microdermics today announced completion of its $1 million financing round, which was oversubscribed and received robust global interest. Microdermics has developed the only commercially scalable, low-cost, customizable, metal, hollow, microneedle platform that provides efficient delivery of vaccines and biologics—addressing the reliance worldwide on the 160-year old, generic hypodermic needle.

The novel drug delivery system uses tiny microneedles that are less than 1 mm long, which provide safer, less painful, more efficient, and more cost-effective means for therapy. Microdermics’ microneedles deliver medicine into the upper dermis; thereby avoiding blood vessels and nerve tissue, resulting in improved biological responses.

“Over 1 billion people around the world suffer from ‘needle phobia’ and avoid injections,” said Grant Campany, president and CEO of Microdermics. “This represents one of the most significant health-related market failures in the world today. On a global level, there’s a staggering amount of people who shun critical therapies or vaccinations because of their fear of hypodermic needles.”

Although microneedle delivery systems have been tried before, they have had limited success due to the materials used (silicon and plastic), which significantly limit their commercial scalability and robustness. Microdermics’ microneedle delivery system are made of metal, and the company’s patented fabrication process is customizable, providing a flexible platform for optimizing the performance of a vaccine or biologic.

Another benefit of Microdermics’ microneedle delivery system is its efficacy. Traditional vaccines currently delivered with a hypodermic needle go into muscle, yet the same vaccine delivered to the upper dermis provides well-documented dose-sparing effects. This presents an entirely new economic model for vaccine companies, since this translates into exponentially higher utilization of either traditional (e.g., flu, rabies) or scarce (e.g., yellow fever) vaccines.

“Our goal is to more efficiently vaccinate high-risk patient populations with a safer, more effective delivery system,” continued Campany.

“Our investment in Microdermics is an example of finding an excellent, well-run company providing a solution to a global need,” said Ray Chan, founding partner of K5 Ventures. “We are so excited to support development and commercialization for this delivery system, which will be beneficial and have a huge impact to so many around the world.”

“Shoreline has been an active investor in the drug formulation and delivery space for some time. When first presented with the Microdermics story it immediately resonated with us. We are always on the lookout for innovative technologies that give the end user a more convenient and less invasive experience and provides superior efficacy for the drugs or vaccines being delivered. Their unique approach addressed both of these and we are delighted to be part of this exciting opportunity," said Peter Craddock, Managing Director of Shoreline Ventures.

"Microdermics’ innovative solution, experienced team, and great potential for positive health impact make it a great addition to the high calibre of new ventures that continue to bloom here at UBC,” Todd Farrell, President e@UBC Seed Fund said.

The financing round included investors from the US, Canada, and Switzerland, and will be used for scale-up and clinical validation studies in support of current and future corporate collaborations. The round closed in March.

“This funding has come at the perfect time for us,” concluded Campany. “It will allow us to execute a few critical hires and invest in infrastructure to support clinical scale-up activities planned for 2017.”

About Microdermics:
Microdermics, In is a Vancouver-based medical device company (with an office in San Francisco) built on research at the University of British Columbia revolutionizing the biopharmaceutical market for both patients and healthcare practitioners. As the only company with a low-cost, scalable, hollow, metal microneedle, Microdermics eliminates the danger of accidental needle sticks caused by hypodermic needles and addresses the global health impact related to needle phobia. Microdermics will leverage its proprietary and innovative delivery system across a spectrum of biopharmaceuticals, including a new market for biosimilars, providing biopharmaceutical companies with a means of differentiating themselves from their competitors as well as securing product life cycle extensions. Learn more at http://www.microdermics.com.

For more information, please contact:

Rory St. Clair
Microdermics Inc.
rory(at)microdermics.com
1.778.938.3108

Kimber Smith Fidler
K5 Ventures for Microdermics
kimber(at)k5launch.com
+1 (714) 267 0219

###

Read the full story at http://www.prweb.com/releases/2017-April/Microdermics/prweb14255813.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. One Minute Herpes Cure Review Discloses the Way to Permanently Treating Herpes
2. The Natural Cure for HPV Review Discloses Andrea Segovia's New Effective HPV Remedy
3. Adonis Golden Ratio Review Discloses the Secrets to the Perfect Body
4. Urticaria Cure By Dr. Gary Levin Review Discloses Natural Way to Overcome Urticaria Fast
5. Shortage of rheumatologists -- In some US regions closest doctor may be 200 miles away
6. Face Fitness Center Review Discloses the Simplest Method to Get Rid of Chubby Cheeks
7. "Cure Hemorrhoids in 48 Hours" Review Discloses New Natural Hemorrhoids Treatment
8. Multiple Sclerosis Treatment Review Discloses New Remedy to Overcome MS Symptoms
9. Heartburn No More Review Discloses the Most Effective Natural Remedy to Stop Pain
10. Catalyze Closes Series A Funding to Expand Development of Its Healthcare Platform
11. Fibroids Miracle Review Discloses the Secrets to Naturally Healing Fibroids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... 2017 , ... NEPC Director Kevin Welner has been awarded ... The award honors scholars exemplary in their capacity to communicate important education research ... the capacity to deepen the public’s understanding and appreciation of the value of ...
(Date:4/24/2017)... ... April 24, 2017 , ... Today, Bright Pink , a national non-profit organization focusing ... a new CEO. , Bright Pink is proud to announce Katie Thiede as their ... to a new role as Chairman of the Board and launched a national search ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the undisputed king of the ... Juicer, and the George Foreman Grill (which sold more than 100 million units worldwide), ... 25 years. , Now, due to changes in the broadcast media landscape, the once ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of Health and ... to track their cognitive health, and share results with their physicians. Members and guests ... the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of ...
(Date:4/24/2017)... Virginia (PRWEB) , ... April 24, 2017 , ... ... announced that they are seeking public support to bring their novel lifesaving device ... appearance, wearable device packed with medical-grade sensors, specially designed to read a child’s ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
(Date:4/18/2017)... , April 18, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a CAGR ... Global Arthroscopy Devices Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/18/2017)... Calif. , April 18, 2017  Socionext ... of collaboration started in 2016, in which Socionext ... Brain SOINN". The companies achieved initial results in ... solution by Artificial Brain SOINN. The results will ... Big Sight, April 19-21, at booths 4505 & ...
Breaking Medicine Technology: